Guardant Health (NASDAQ:GH) Receives “Overweight” Rating from Stephens

Stephens restated their overweight rating on shares of Guardant Health (NASDAQ:GH) in a research report released on Wednesday,Benzinga reports. Stephens currently has a $55.00 price target on the stock.

A number of other brokerages also recently issued reports on GH. Guggenheim reissued a “buy” rating and issued a $56.00 target price on shares of Guardant Health in a report on Monday, February 24th. Piper Sandler increased their price objective on shares of Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. The Goldman Sachs Group lifted their target price on shares of Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. increased their price target on Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Finally, Morgan Stanley boosted their price objective on Guardant Health from $42.00 to $52.00 and gave the company an “overweight” rating in a research report on Thursday, March 6th. Twenty investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $48.95.

Guardant Health Trading Down 1.3 %

GH opened at $45.84 on Wednesday. The firm’s 50 day simple moving average is $44.37 and its two-hundred day simple moving average is $34.03. The company has a market capitalization of $5.66 billion, a PE ratio of -12.88 and a beta of 1.50. Guardant Health has a 1-year low of $15.81 and a 1-year high of $50.89.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The company had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Equities analysts forecast that Guardant Health will post -2.9 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Guardant Health

Several institutional investors have recently bought and sold shares of GH. Intech Investment Management LLC purchased a new stake in Guardant Health during the third quarter valued at approximately $754,000. Cerity Partners LLC increased its position in shares of Guardant Health by 54.6% during the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company’s stock valued at $4,473,000 after purchasing an additional 68,883 shares during the last quarter. Advantage Alpha Capital Partners LP purchased a new stake in Guardant Health during the 3rd quarter valued at $343,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Guardant Health by 6.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,986 shares of the company’s stock worth $665,000 after buying an additional 1,844 shares during the last quarter. Finally, Verition Fund Management LLC boosted its stake in Guardant Health by 220.6% during the third quarter. Verition Fund Management LLC now owns 37,641 shares of the company’s stock worth $863,000 after buying an additional 25,900 shares during the period. Institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.